ClinicalTrials.gg

Program

Pan-KRAS Inhibitor JAB-23E73

Its studies are mostly in Pancreatic Neoplasms, led by Jacobio Pharmaceuticals.

Furthest: phase 2, since Apr 24, 20252 company-led studies, 2 open or runningNext primary completion: Dec 31, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jacobio Pharmaceuticals22 open or runningphase 2since Apr 24, 2025Apr 24, 2025Dec 31, 2026phase 2 · NCT06959615
  • Named in astrazeneca’s own pipeline as JAB-23E73, phase 1, as of Oct 30, 2026 (source).

Also a collaborator on its studies: AstraZeneca.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 24, 2025First studies: 2 phase 2 studies in Pancreatic NeoplasmsFirst studyNCT06973564, NCT06959615

Ahead

  1. Dec 31, 2026Primary completion: phase 2 study in Pancreatic NeoplasmsNCT06959615
  2. Nov 2028Primary completion: phase 2 study in Pancreatic NeoplasmsNCT06973564

TargetBeta

“An orally bioavailable inhibitor of both the active, guanosine triphosphate (GTP)-bound (ON) form and the inactive, guanosine diphosphate (GDP)-bound (OFF) form of various oncogenic KRAS mutations, with potential antineoplastic activity. Upon oral administration, pan-KRAS inhibitor JAB-23E73 targ…”NCIt, read by Claude
“An orally bioavailable inhibitor of both the active, guanosine triphosphate (GTP)-bound (ON) form and the inactive, guanosine diphosphate (GDP)-bound (OFF) form of various oncogenic KRAS mutations, ”NCIt, by rule

Other programs on KRAS

ProgramCompanyFurthest phaseStudies
sotorasibruleAmgenphase 328
adagrasibruleBristol-Myers Squibbphase 316
olomorasibEli Lillyphase 316
divarasibHoffmann-La Rochephase 313
KRAS G12D Inhibitor VS-7375ruleGenfleet Therapeutics (Shanghai)phase 312
glecirasibruleAllist Pharmaceuticalsphase 312
calderasibMerckphase 312
daraxonrasibruleRevolution Medicinesphase 310
garsorasibruleInventisBiophase 38
KRAS G12D Inhibitor HRS-4642Jiangsu HengRui Medicinephase 37
zoldonrasibruleRevolution Medicinesphase 36
HRS-7058Jiangsu HengRui Medicinephase 36

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06959615Pancreatic Neoplasms · China2RecruitingDec 31, 2026334
NCT06973564Pancreatic Neoplasms · United States2RecruitingNov 2028344

How it is read

Names in the registry

  • “JAB-23E73”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.